Table 1.
Samples’ characteristics of the 20 individuals enrolled in the study against study groups.
| Overall N = 20 | Study group | ||||
|---|---|---|---|---|---|
| Molnupiravir treated N = 8 | Paxlovid treated N = 7 | Drug Naïve N = 5 | p-value | ||
| Sex, Malea | 11 (55.0) | 5 (62.5) | 3 (42.8) | 3 (60.0) | 0.723 |
| Age (years)a | 51 (18–62) | 58 (51–69) | 61 (46–63) | 7 (2–11) | 0.005 |
| Presence of at least one comorbiditya | 18 (90.0) | 8 (100.0) | 7 (100.0) | 3 (60.0) | 0.036 |
| Start of Symptomsa | 02 May 2022 (27 Apr 2022–12 May 2022) | 02 May 2022 (02 May 2022–12 May 2022) | 30 Apr 2022 (27 Apr 2022–26 May 2022) | 01 Apr 2022 (23 March 2022–21 Apr 2022) | 0.150 |
| First positivitya | 02 May 2022 (28 Apr 2022–11 May 2022) | 03 May 2022 (02 May 2022–12 May 2022) | 01 May 2022 (29 Apr 2022–27 May 2022) | 01 Apr 2022 (26 March 2022–28 Apr 2022) | 0.033 |
| Lineages:a | |||||
| BA.2 | 4 (20.0) | 1 (12.5) | 2 (28.6) | 1 (20.0) | 0.739 |
| BA.2.9 | 10 (50.0) | 7 (87.5) | 0 (0.0) | 3 (60.0) | 0.002 |
| BA.2.12/BA.2.12.1 | 3 (15.0) | 0 (0.0) | 3 (42.8) | 0 (0.0) | 0.047 |
| BA.2.3/BA.2.3.15 | 3 (15.0) | 0 (0.0) | 2 (28.6) | 1 (20.0) | 0.283 |
| SARS-CoV-2 RNA at Day 0b | 7.2 (6.5-7.7) | 7.1 (6.5-7.3) | 7.2 (6.5-7.7) | 7.7 (7.4-8.0) | 0.134 |
| SARS-CoV-2 RNA at Day 2b | 5.1 (4.0-6.3) | 4.8 (3.4-5.8) | 5.4 (4.2-5.8) | 6.5 (5.0-7.9) | 0.193 |
| SARS-CoV-2 RNA at Day 5b | 4.3 (3.5-6.0) | 3.6 (1.6-4.5) | 5.4 (3.5-6.0) | 6.4 (5.1-7.0) | 0.008 |
| SARS-CoV-2 RNA at Day 7b | 4.0 (0.0-5.5) | 3.1 (0.0-4.5) | 4.8 (3.5-5.4) | 5.5 (3.4-6.6) | 0.083 |
Data are expressed as median (IQR), or N (%).
aTwo-sided P-values were calculated by Kruskal–Wallis test, or Chi-square test, as appropriate.
bTwo-sided P-values were calculated by Jonckheere-Terpstra test. SARS-CoV-2 RNA was expressed as log10 copies/mL.